Error loading player: No playable sources found

Plenary Session 1 - Novel Modalities

Date
January 23, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Technological innovation and advancements have enabled novel designs for antibody-based products, vaccines, blood products, gene and cell therapy candidates. While mAB conjugates like ADCs and novel mAB constructs like bispecifics molecules have been maturing as approved therapies for unmet medical needs, additional molecules like mAb fragments, trispecifics, cocktails, bifunctional (e.g., mAb-cytokine fusion proteins), and non-IgG isotype molecules are in development. Novel approaches to vaccine design include the expression of antigen to elicit a protective immune response and development of universal vaccines for flu and SARS-CoV-2. Gene and cell therapies continue to evolve, including new designs for CAR-T cell constructs to decrease side effects, improve proliferation and cytotoxicity, and increase specificity of therapeutic targets.  The emerging allogenic/ Induced Pluripotent Stem Cells (IPSC) CAR-T cells will further the reach of CAR-T applications.  In addition, macrophage CAR which are in development may better target solid tumors. This springs the questions, do novel modalities warrant novel product quality controls because of product quality concerns? It is acknowledged that based on the modality, additional testing based on novel analytical techniques, control and characterization may be recommended and should be determined on an individual case basis. This should be informed by scientific knowledge and risk-based approach aligned with guidance documents. In this session we will discuss the industry’s current trend and application of innovative approaches for new modalities, with a focus on the success, challenges, and lessons learned during product development. 


Session Speakers:


Enhanced Quality Attribute Understanding Enabled Accelerated Development of a RSV Vaccine

John Davis, Pfizer, Inc.


Analytical Considerations in the Development of Engineered Therapeutic IgM Antibodies

Devinder Ubhi, IGM Biosciences, Inc.

Jaime Marach, IGM Biosciences, Inc.


6+ Years of Autologous CAR-T Therapy  

Mehrshid Alai-Safar, Kite, a Gilead Company


Related Products

Thumbnail for Potency Assays for ATMPs – Selection of Assay Platforms and Data Processing Methods are Key Aspects for Successful Control Strategies | Presented by BioAgilytix Labs, LLC
Potency Assays for ATMPs – Selection of Assay Platforms and Data Processing Methods are Key Aspects for Successful Control Strategies | Presented by BioAgilytix Labs, LLC
POTENCY ASSAYS FOR ATMPS – SELECTION OF ASSAY PLATFORMS AND DATA PROCESSING METHODS ARE KEY ASPECTS FOR SUCCESSFUL CONTROL STRATEGIES
Thumbnail for Host Cell Protein ELISAs: The Scientific and Business Decisions to Ensure Successful Outcomes | Presented by Cygnus Technologies, LLC
Host Cell Protein ELISAs: The Scientific and Business Decisions to Ensure Successful Outcomes | Presented by Cygnus Technologies, LLC
HOST CELL PROTEIN ELISAS: THE SCIENTIFIC AND BUSINESS DECISIONS TO ENSURE SUCCESSFUL OUTCOMES
Thumbnail for Welcome Day 2 & CASSS Distinguished Fellows Awards
Welcome Day 2 & CASSS Distinguished Fellows Awards
The designation of CASSS Distinguished Fellow is designed to recognize individuals noted for their outstanding contributions to CASSS, our community and the industry overall…
Thumbnail for Plenary Session 6: Clearing the Fog: Particle Visibility and Regulatory Updates for Visual Inspection of Parenteral Drug Products and WCBP 2024 Closing Remarks
Plenary Session 6: Clearing the Fog: Particle Visibility and Regulatory Updates for Visual Inspection of Parenteral Drug Products and WCBP 2024 Closing Remarks
Visual inspection of parenteral drug products is a critical aspect of pharmaceutical development and manufacturing, subject to evolving regulatory standards…